AstraZeneca spending £120m on Macclesfield manufacturing revamp
This article was originally published in Scrip
Executive Summary
AstraZeneca is investing £120m ($190m) in a new facility at its global manufacturing site in Macclesfield, UK, to continue production of injectable prostate and breast cancer drug Zoladex.